12:18 PM
 | 
Sep 12, 2017
 |  BC Extra  |  Company News

Harbour gets Chinese rights to HanAll's biologics

Korean biotech HanAll Biopharma Co. Ltd. (KOSDAQ:009420) granted Harbour BioMed (Shanghai, China) rights to develop and commercialize HL161 and HL036 in China, including Hong Kong and Macau, and Taiwan. HanAll retains rights elsewhere.

HanAll is eligible to receive up to $81 million in an upfront and milestone payments,...

Read the full 237 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >